Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). UroGen Pharma's share price for the quarter that ended in Mar. 2025 was $11.06. UroGen Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 46.10 Mil. Therefore, UroGen Pharma's market cap for the quarter that ended in Mar. 2025 was $509.89 Mil.
UroGen Pharma's quarterly market cap
declined
from Sep. 2024 ($535.83 Mil) to Dec. 2024 ($449.77 Mil) but then
increased
from Dec. 2024 ($449.77 Mil) to Mar. 2025 ($509.89 Mil).
UroGen Pharma's annual market cap
increased
from Dec. 2022 ($205.16 Mil) to Dec. 2023 ($487.35 Mil) but then
declined
from Dec. 2023 ($487.35 Mil) to Dec. 2024 ($449.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. UroGen Pharma's Enterprise Value for Today is $639.58 Mil.
UroGen Pharma Market Cap Historical Data
The historical data trend for UroGen Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of UroGen Pharma's Market Cap
For the Biotechnology subindustry, UroGen Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
UroGen Pharma's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (NAS:URGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
UroGen Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your 